DAX15.909 -0,3%ESt504.292 -0,7%TDax3.219 -0,2%Dow33.043 -0,2%Nas13.017 +0,3%Bitcoin25.901 -0,1%Euro1,0735 +0,2%Öl73,69 -4,3%Gold1.960 +0,9%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 BVB (Borussia Dortmund) 549309 Tesla A1CX3T Amazon 906866 Uniper UNSE01 Microsoft 870747 Mercedes-Benz Group (ex Daimler) 710000 Apple 865985 NEL ASA A0B733 BASF BASF11 Volkswagen (VW) vz. 766403 Deutsche Bank 514000 Commerzbank CBK100 TUI TUAG50 Allianz 840400
Alle Aktien für 0 Euro handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Vorläufige Einigung im US-Schuldenstreit: DAX schließt schwächer -- Wall Street letztlich uneins -- Aroundtown bekräftigt Ausblick -- SFC Energy, TUI, Uniper, Daimler Truck, NVIDIA im Fokus
Top News
NASDAQ-Wert NVIDIA-Aktie stärker: NVIDIA will Chatbot-Technik zur Verbesserung von Videospiel-Unterhaltungen einsetzen
IMI-Aktie: JPMorgan erwartet im Juni Veränderungen im FTSE 100
Suche...
Login

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Sanofi Aktie

Kaufen
Verkaufen
Sanofi Aktien-Sparplan
94,46 EUR -4,28 EUR -4,33 %
FSE
96,35 EUR -2,72 EUR -2,75 %
GVIE
Aktien, ETFs, Sparpläne & Kryptos ohne Gebühren beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN UND GRATIS-AKTIE BEKOMMEN
Du hast schon ein Konto? Hier verknüpfen
Marktkap.124,64 Mrd. EURKGV10,97

WKN 920657

ISIN FR0000120578

Symbol SNYNF

Sanofi Aktien News

DatumMeistgelesen
GlobeNewswirePress Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors
EN, Sanofi-AventisPress Release: Annual General Meeting of May 25, 2023 - Frédéric Oudéa new Chairman of the Board of Directors
BenzingaSanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained
WerbungSanofi-Aktie für 0 Euro handeln bei finanzen.net zero
GlobeNewswirePress Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
EN, Sanofi-AventisPress Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares – April 2023
BenzingaRebates or Patent Abuse? Eli Lilly, Novo Nordisk, and Sanofi CEOs Cross Swords with PBMs in Senate Hearing
BenzingaSanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody
EN, Sanofi-AventisPress Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
GlobeNewswirePress Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
BenzingaFabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
BenzingaObesity Drug Achieves ~15% Weight Loss - Zealand Pharma-Boehringer Ingelheim Partnered Drug May Compete With Novo Nordisk, Eli Lilly
EN, Sanofi-AventisMedia Update: Positive data from two Phase 3 Dupixent® (dupilumab) trials in prurigo nodularis published in Nature Medicine
EN, Sanofi-AventisMedia Update: New late-breaking data at ATS 2023 demonstrate significant advancements across Dupixent® and broader respiratory pipeline
GlobeNewswireSanofi: COMBINED GENERAL MEETING OF MAY 25, 2023 - AVAILABILITY OF PREPARATORY DOCUMENTS
BenzingaSanofi In-Licenses Pompe Disease Therapy From Privately-Held Maze Therapeutics For $150M Upfront
MotleyFoolSanofi (SNY) Q1 2023 Earnings Call Transcript
BenzingaSanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales
ZacksSanofi (SNY) Q1 Earnings Beat, Sales Miss, Dupixent Strong
GlobeNewswirePress Release: Sanofi completes acquisition of Provention Bio, Inc.
EN, Sanofi-AventisPress Release: Sanofi completes acquisition of Provention Bio, Inc.
InvestegateSanofi - Aventis Groupe : Press Release: Sanofi completes acquisition of Provention Bio, Inc.
MarketWatchDow Jones Newswires: Sanofi backs guidance as it reports higher sales
EN, Sanofi-AventisPress Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC
GlobeNewswirePress Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC
InvestegateSanofi - Aventis Groupe : Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC
BenzingaEarnings Outlook For Sanofi
ZacksIs a Surprise Coming for Sanofi (SNY) This Earnings Season?
EN, Sanofi-AventisPress Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.
GlobeNewswirePress Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.
ZacksSanofi (SNY) is a Great Momentum Stock: Should You Buy?
ZacksSanofi (SNY) Stock Moves -0.45%: What You Should Know
ZacksZacks.com featured highlights include Unum, Graphic Packaging Holding, AutoNation and Sanofi
ZacksWill Sanofi (SNY) Surpass Estimates This Earnings Season?
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - March 2023
ZacksZacks.com featured highlights include Unum Group, Sanofi, KB Home, PVH and Telefonica Brasil
ZacksZacks.com featured highlights include Sanofi, Medallion Financial, Plains All American Pipeline and KB Home
Zacks3 Reasons Growth Investors Will Love Sanofi (SNY)
EN, Sanofi-AventisPress Release: Elisabeth Moreno to join Sanofi's Diversity, Equity and Inclusion Board
ZacksAstraZeneca (AZN), Sanofi Simply RSV Antibody Agreement Terms

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.